163 related articles for article (PubMed ID: 26152744)
1. Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337).
Dietsch GN; Randall TD; Gottardo R; Northfelt DW; Ramanathan RK; Cohen PA; Manjarrez KL; Newkirk M; Bryan JK; Hershberg RM
Clin Cancer Res; 2015 Dec; 21(24):5445-52. PubMed ID: 26152744
[TBL] [Abstract][Full Text] [Related]
2. Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity.
Dietsch GN; Lu H; Yang Y; Morishima C; Chow LQ; Disis ML; Hershberg RM
PLoS One; 2016; 11(2):e0148764. PubMed ID: 26928328
[TBL] [Abstract][Full Text] [Related]
3. Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.
Chow LQM; Morishima C; Eaton KD; Baik CS; Goulart BH; Anderson LN; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Disis ML; Martins RG
Clin Cancer Res; 2017 May; 23(10):2442-2450. PubMed ID: 27810904
[No Abstract] [Full Text] [Related]
4. Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.
Monk BJ; Facciabene A; Brady WE; Aghajanian CA; Fracasso PM; Walker JL; Lankes HA; Manjarrez KL; Danet-Desnoyers GH; Bell-McGuinn KM; McCourt CK; Malykhin A; Hershberg RM; Coukos G
Clin Cancer Res; 2017 Apr; 23(8):1955-1966. PubMed ID: 27702821
[No Abstract] [Full Text] [Related]
5. The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent.
Cheng Y; Borcherding N; Ogunsakin A; Lemke-Miltner CD; Gibson-Corley KN; Rajan A; Choi AB; Wongpattaraworakul W; Chan CHF; Salem AK; Weiner GJ; Simons AL
Sci Rep; 2021 Jan; 11(1):1535. PubMed ID: 33452311
[TBL] [Abstract][Full Text] [Related]
6. Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.
Shayan G; Kansy BA; Gibson SP; Srivastava RM; Bryan JK; Bauman JE; Ohr J; Kim S; Duvvuri U; Clump DA; Heron DE; Johnson JT; Hershberg RM; Ferris RL
Clin Cancer Res; 2018 Jan; 24(1):62-72. PubMed ID: 29061643
[No Abstract] [Full Text] [Related]
7. TLR8 ligation induces apoptosis of monocytic myeloid-derived suppressor cells.
Dang Y; Rutnam ZJ; Dietsch G; Lu H; Yang Y; Hershberg R; Disis ML
J Leukoc Biol; 2018 Jan; 103(1):157-164. PubMed ID: 29345064
[TBL] [Abstract][Full Text] [Related]
8. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.
Ferris RL; Saba NF; Gitlitz BJ; Haddad R; Sukari A; Neupane P; Morris JC; Misiukiewicz K; Bauman JE; Fenton M; Jimeno A; Adkins DR; Schneider CJ; Sacco AG; Shirai K; Bowles DW; Gibson M; Nwizu T; Gottardo R; Manjarrez KL; Dietsch GN; Bryan JK; Hershberg RM; Cohen EEW
JAMA Oncol; 2018 Nov; 4(11):1583-1588. PubMed ID: 29931076
[TBL] [Abstract][Full Text] [Related]
9. The ultra-potent and selective TLR8 agonist VTX-294 activates human newborn and adult leukocytes.
Dowling DJ; Tan Z; Prokopowicz ZM; Palmer CD; Matthews MA; Dietsch GN; Hershberg RM; Levy O
PLoS One; 2013; 8(3):e58164. PubMed ID: 23483986
[TBL] [Abstract][Full Text] [Related]
10. A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma.
Northfelt DW; Ramanathan RK; Cohen PA; Von Hoff DD; Weiss GJ; Dietsch GN; Manjarrez KL; Randall TD; Hershberg RM
Clin Cancer Res; 2014 Jul; 20(14):3683-91. PubMed ID: 24807889
[TBL] [Abstract][Full Text] [Related]
11. VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.
Lu H; Dietsch GN; Matthews MA; Yang Y; Ghanekar S; Inokuma M; Suni M; Maino VC; Henderson KE; Howbert JJ; Disis ML; Hershberg RM
Clin Cancer Res; 2012 Jan; 18(2):499-509. PubMed ID: 22128302
[TBL] [Abstract][Full Text] [Related]
12. In vitro metabolic profiles of motolimod by using liquid chromatography tandem mass spectrometry: Metabolic stability, metabolite characterization and species comparison.
Li Z; Zhao S; Yuan Y; Zhang L; Song Z; Tian X; Zhang X
J Pharm Biomed Anal; 2019 Apr; 167():90-99. PubMed ID: 30763883
[TBL] [Abstract][Full Text] [Related]
13. Trial Watch: experimental TLR7/TLR8 agonists for oncological indications.
Frega G; Wu Q; Le Naour J; Vacchelli E; Galluzzi L; Kroemer G; Kepp O
Oncoimmunology; 2020 Jul; 9(1):1796002. PubMed ID: 32934889
[TBL] [Abstract][Full Text] [Related]
14. Motolimod effectively drives immune activation in advanced cancer patients.
Dietsch GN
Oncoimmunology; 2016 May; 5(5):e1126037. PubMed ID: 27467937
[TBL] [Abstract][Full Text] [Related]
15. TLR8 agonist Motolimod-induced inflammatory death for treatment of acute myeloid leukemia.
Yang W; Sun X; Liu S; Xu Y; Li Y; Huang X; Liu K; Mao L; Min S; Liu L; Li S; Zhu Y; Zhang Y; Xie X; Xu K; Sun C; Yan J; Li Z
Biomed Pharmacother; 2023 Jul; 163():114759. PubMed ID: 37105077
[TBL] [Abstract][Full Text] [Related]
16. Determination of motolimod concentration in rat plasma by liquid chromatography-tandem mass spectrometry and its application in a pharmacokinetic study.
Ji YG; Shin YM; Jeong JW; Choi HI; Lee SW; Lee JH; Lee KR; Koo TS
J Pharm Biomed Anal; 2020 Feb; 179():112987. PubMed ID: 31761376
[TBL] [Abstract][Full Text] [Related]
17. Identification of new potent agonists for toll-like receptor 8 by virtual screening methods, molecular dynamics simulation, and MM-GBSA.
Sadeghkhani F; Hajihassan Z; Gharaghani S
J Biomol Struct Dyn; 2023 Nov; 41(19):10026-10036. PubMed ID: 36469705
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy.
Wang Z; Gao Y; He L; Sun S; Xia T; Hu L; Yao L; Wang L; Li D; Shi H; Liao X
J Med Chem; 2021 Jun; 64(11):7507-7532. PubMed ID: 34048243
[TBL] [Abstract][Full Text] [Related]
19. Activation of the Toll-like receptor 8 pathway increases the immunogenicity of mesenchymal stem cells from umbilical cord.
Yang Y; Wang Y; Li L; Chen F; Zhang P
Mol Med Rep; 2017 Aug; 16(2):2061-2068. PubMed ID: 28656222
[TBL] [Abstract][Full Text] [Related]
20. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
